Bioventus (US:BVS)2025-08-12 18:00Financial Performance & Growth - The company's last twelve months (LTM) global proforma revenue is $564 million[6] - The company is experiencing above-market revenue growth, with seven quarters of mid-single-digit or higher growth[7] - The company's organic growth is projected at 7.0% in 2025[11] - The company's Adjusted EBITDA margin is steadily increasing, projected to reach 20.2% in 2025[14] - Cash from operations is increasing, with 2025 projected to be nearly double that of 2024[18] - Net leverage ratio is decreasing, projected to be less than 2.5x by the end of 2025[28] Market & Strategy - The company operates in a $6.4 billion addressable market[6] - The company has a diversified portfolio across Pain Treatments, Surgical Solutions, and Restorative Therapies[5, 20] - The company is focused on margin expansion by leveraging mid-70s gross margin and cost efficiencies[7, 25] - The company aims to nearly double 2024 free cash flow in 2025, with a cash flow yield of approximately 60%[28]